Company intelligence / Profile preview
Immunocore
Abingdon, Oxfordshire, United Kingdomimmunocore.com ↗
- Ownership
- Public · IMCR
- Development stage
- Commercial
01
Overview
Immunocore discovered, developed and commercialized the world's first approved T cell receptor (TCR) therapy. Their lead product, Kimmtrak (tebentafusp), is approved for metastatic uveal melanoma and is being tested in advanced cutaneous melanoma and adjuvant uveal melanoma.
- Therapeutic areas
- ImmunologyEndocrinologyDermatologyOncologyInfectious Diseases
- Modalities
- T cell receptor (TCR) bispecific immunotherapiesImmTAX molecules
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
Request access →03
Partnerships
GenentechGSKBill & Melinda Gates FoundationEORTC
04
Financials
- Market cap
- $1.8B
- Total revenue
- $115.9M
- Enterprise value
- $1.3B
Beyond the preview
Go deeper on Immunocore.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunocore.